To evaluate changes in tear secretion and symptoms in patients with mild dry eye syndrome after using Restasis®.

From patients diagnosed with mild dry eye syndrome, Restasis® was administered to 46 eyes of 23 patients. The clinical parameters and symptoms were checked over a period of six months. The clinical parameters evaluated were the symptoms of dry eye syndrome using an OSDI scoring scale, the Schirmer test, and tear break-up time.

Eight male patients and 15 female patients were included in the study. The mean age was 50.5 years. Before treatment, the values for the OSDI score, BUT, and Schirmer test were 32.3, 5.3 mm, and 8.1 seconds, respectively. After treatment, the OSDI score, BUT, and Schirmer test were 22.9, 8.1 mm, and 12.1 seconds at six months, respectively. The subjective parameter (OSDI score) improved two months after treatment ( p =0.003), and the objective parameters (BUT, Schirmer test) improved three months after treatment ( p =0.03, p =0.04, respectively).

In the present study, Restasis® increased tear secretion and improved clinical symptoms of patients with mild dry eye.